 The
KURE ETF, or the KS MSCI All China Health Care Index ETF, is an
exchange-traded fund that seeks to track the performance of the MSCI
China All Shares Health Care 10/40 Index. The index is designed to
measure the performance of companies in the health care sector listed
on the Hong Kong Stock Exchange (HKEX), the Shanghai Stock Exchange
(SSE), and the Shenzhen Stock Exchange (SZSE).
As of the most
recent report, the fund had total assets under management of
approximately $155 million and an expense ratio of 0.65%. The fund's
top holdings included companies such as Jiangsu Hengrui Medicine Co.,
CSPC Pharmaceutical Group Ltd., and Wuxi Biologics (Cayman) Inc.,
among others. The fund has a concentrated portfolio, with its top 10
holdings representing approximately 58% of the total portfolio.
In terms of performance, the KURE ETF has had mixed performance in
recent years. As of the end of 2021, the fund had a year-to-date
return of approximately -9.4%, a one-year return of approximately
4.1%, and a three-year average annual return of approximately 24.2%.
It's important to note that the performance of the fund can be
influenced by various factors, including changes in the Chinese stock
markets, regulatory developments, and company-specific factors.
Overall, the KURE ETF offers investors exposure to the
fast-growing health care sector in China, which is expected to benefit
from an aging population and increasing demand for health care
services. However, investors should be aware of the risks associated
with investing in Chinese companies, which include regulatory risk,
currency risk, and geopolitical risk. Additionally, the fund's
concentrated portfolio may make it more volatile compared to more
diversified ETFs.
|
